Scholarlink

Aims <p>Glucagon-like peptide-1 receptor (GLP-1R) has become one of the most promising ligand-receptor systems to target for type 2 diabetes mellitus (T2DM) treatment. Over the last two decades, several GLP-1 receptor agonists (GLP-1RAs) have been developed and semaglutide is the first and only GLP-1RA available as an oral formulation<i>. GLP1R</i> single nucleotide polymorphisms may affect GLP-1R response to oral semaglutide. Here we aimed to evaluate the impact of <i>rs6923761</i> and <i>rs761387 GLP1R</i> polymorphisms on the response to oral semaglutide.</p> Methods <p>This is a retrospective cohort study including adult patients with T2DM who had been treated with oral semaglutide for at least one year. Patients were enrolled between November 2023 and April 2024, and then genotyped.</p> Results <p>We selected 210 adult patients with a median age of 71&#xa0;years. Their median BMI was 29.1&#xa0;kg/m<sup>2</sup>, HbA1c was 7.2% (55&#xa0;mmol/mol), duration of diabetes was 12&#xa0;years. After a median follow-up of 18&#xa0;months, oral semaglutide reduced HbA1c by −0.3% (−3&#xa0;mmol/mol), BMI by −1.1&#xa0;kg/m2, SBP by −5&#xa0;mmHg, total cholesterol by -8&#xa0;mg/dL, triglycerides by -6.5&#xa0;mg/dL. In addition, a reduction of ACR by −44.02&#xa0;mg/g was observed in patients with baseline ACR &gt; 30&#xa0;mg/g, along with a decrease of liver transaminases in patients with baseline levels ≥ 35 U/L. Multivariate linear regression did not show any significant association between <i>rs6923761</i> or <i>rs761387 GLP1R</i> genotypes and changes in HbA1c, BMI, SBP and DBP.</p> Conclusions <p>Our findings confirm the effectiveness of oral semaglutide in improving metabolic control and providing cardiorenal protection in different clinical scenarios. Conversely, they fail to show a clear benefit of <i>GLP1R</i> genotyping to guide treatment decisions, at least in patients with HbA1c &lt; 7.5% (&lt; 58&#xa0;mmol/mol). Further studies are needed to confirm and extend our findings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Influence of GLP1 receptor rs6923761 and rs761387 genetic variants on oral semaglutide response in patients with type 2 diabetes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月27日

查看全文
  • Riccardo Candido,
  • Barbara Toffoli,
  • Gabriele Baccichetto,
  • Francesca Marchese,
  • Silvia Carpenè,
  • Sara Gaiotti,
  • Bruno Fabris,
  • Stella Bernardi

摘要

Aims

Glucagon-like peptide-1 receptor (GLP-1R) has become one of the most promising ligand-receptor systems to target for type 2 diabetes mellitus (T2DM) treatment. Over the last two decades, several GLP-1 receptor agonists (GLP-1RAs) have been developed and semaglutide is the first and only GLP-1RA available as an oral formulation. GLP1R single nucleotide polymorphisms may affect GLP-1R response to oral semaglutide. Here we aimed to evaluate the impact of rs6923761 and rs761387 GLP1R polymorphisms on the response to oral semaglutide.

Methods

This is a retrospective cohort study including adult patients with T2DM who had been treated with oral semaglutide for at least one year. Patients were enrolled between November 2023 and April 2024, and then genotyped.

Results

We selected 210 adult patients with a median age of 71 years. Their median BMI was 29.1 kg/m2, HbA1c was 7.2% (55 mmol/mol), duration of diabetes was 12 years. After a median follow-up of 18 months, oral semaglutide reduced HbA1c by −0.3% (−3 mmol/mol), BMI by −1.1 kg/m2, SBP by −5 mmHg, total cholesterol by -8 mg/dL, triglycerides by -6.5 mg/dL. In addition, a reduction of ACR by −44.02 mg/g was observed in patients with baseline ACR > 30 mg/g, along with a decrease of liver transaminases in patients with baseline levels ≥ 35 U/L. Multivariate linear regression did not show any significant association between rs6923761 or rs761387 GLP1R genotypes and changes in HbA1c, BMI, SBP and DBP.

Conclusions

Our findings confirm the effectiveness of oral semaglutide in improving metabolic control and providing cardiorenal protection in different clinical scenarios. Conversely, they fail to show a clear benefit of GLP1R genotyping to guide treatment decisions, at least in patients with HbA1c < 7.5% (< 58 mmol/mol). Further studies are needed to confirm and extend our findings.